The Phase 3 INVIGORATE Trial of Reproxalap in Patients with Seasonal Allergic Conjunctivitis

References

• Higdon A, Diers AR, Oh JY, et al. Cell signalling by reactive lipid species: new concepts and molecular mechanisms. Biochem J. 2012;442(3):453–464. doi:10.1042/bj20111752
   PubMedGoogle Scholar
• Kalariya NM, Ramana KV, Srivastava SK, et al. Carotenoid derived aldehydes-induced oxidative stress causes apoptotic cell death in human retinal pigment epithelial cells. Exp Eye Res. 2008;86(1):70–80. doi:10.1016/j.exer.2007.09.010
   PubMed Web of Science ®Google Scholar
• Kauppinen A, Niskanen H, Suuronen T, et al. Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells--implications for age-related macular degeneration (AMD). Immunol Lett. 2012;147(1–2):29–33. doi:10.1016/j.imlet.2012.05.005
   PubMed Web of Science ®Google Scholar
• Matés JM, Segura JM, Pérez-Gómez C, et al. Antioxidant enzymatic activities in human blood cells after an allergic reaction to pollen or house dust mite. Blood Cells Mol Dis. 1999;25(2):103–109. doi:10.1006/bcmd.1999.0234
   PubMedGoogle Scholar
• Wakamatsu TH, Dogru M, Ayako I, et al. Evaluation of lipid oxidative stress status and inflammation in atopic ocular surface disease. Mol Vis. 2010;16:2465–2475.
   PubMed Web of Science ®Google Scholar
• Ackerman S, Smith LM, Gomes PJ. Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management. Ther Adv Chronic Dis. 2016;7(1):52–67. doi:10.1177/2040622315612745
   PubMed Web of Science ®Google Scholar
• Clark D, Cavanagh B, Shields AL, et al. Clinically relevant activity of the novel RASP inhibitor reproxalap in allergic conjunctivitis: the Phase 3 ALLEVIATE Trial. Am J Ophthalmol. 2021;230:60–67. doi:10.1016/j.ajo.2021.04.023
   PubMed Web of Science ®Google Scholar
• Clark D, Karpecki P, Salapatek AM, et al. Reproxalap improves signs and symptoms of allergic conjunctivitis in an allergen chamber: a real-world model of allergen exposure. Clin Ophthalmol. 2022;16:15–23. doi:10.2147/opth.S345324
   PubMed Web of Science ®Google Scholar
• Cavanagh B, Gomes PJ, Starr CE, et al. Reproxalap activity and estimation of clinically relevant thresholds for ocular itching and redness in a randomized allergic conjunctivitis field trial. Ophthalmol Ther. 2022;11(4):1449–1461. doi:10.1007/s40123-022-00520-z
   PubMed Web of Science ®Google Scholar
• Mandell KJ, Clark D, Chu DS, et al. Randomized Phase 2 trial of reproxalap, a novel reactive aldehyde species inhibitor, in patients with noninfectious anterior uveitis: model for corticosteroid replacement. J Ocul Pharmacol Ther. 2020;36(10):732–739. doi:10.1089/jop.2020.0056
   PubMed Web of Science ®Google Scholar
• Clark D, Sheppard J, Brady TC. A randomized double-masked phase 2a trial to evaluate activity and safety of topical ocular reproxalap, a novel RASP inhibitor, in dry eye disease. J Ocul Pharmacol Ther. 2021;37(4):193–199. doi:10.1089/jop.2020.0087
   PubMed Web of Science ®Google Scholar
• Clark D, Tauber J, Sheppard J, et al. Early onset and broad activity of reproxalap in a randomized, double-masked, vehicle-controlled phase 2b trial in dry eye disease. Am J Ophthalmol. 2021;226:22–31. doi:10.1016/j.ajo.2021.01.011
   PubMed Web of Science ®Google Scholar
• Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988-1994. J Allergy Clin Immunol. 2010;126(4):778–783.e6. doi:10.1016/j.jaci.2010.06.050
   PubMed Web of Science ®Google Scholar
• Leonardi A, Piliego F, Castegnaro A, et al. Allergic conjunctivitis: a cross-sectional study. Clin Exp Allergy. 2015;45(6):1118–1125. doi:10.1111/cea.12536
   PubMed Web of Science ®Google Scholar
• McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 2002;25(1):33–55. doi:10.2165/00002018-200225010-00004
   PubMed Web of Science ®Google Scholar
• Torkildsen G, Narvekar A, Bergmann M. Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model. Clin Ophthalmol. 2015;9:1703–1713. doi:10.2147/opth.S83263
   PubMedGoogle Scholar
• Leonardi A. Role of histamine in allergic conjunctivitis. Acta Ophthalmol Scand Suppl. 2000;230:18–21. doi:10.1034/j.1600-0420.2000.078s230018.x
   Google Scholar
• Rønborg SM, Mosbech H, Johnsen CR, et al. Exposure chamber for allergen challenge. The development and validation of a new concept. Allergy. 1996;51(2):82–88. doi:10.1111/j.1398-9995.1996.tb04562.x
   PubMed Web of Science ®Google Scholar
• Schulze MM, Jones DA, Simpson TL. The development of validated bulbar redness grading scales. Optom Vis Sci. 2007;84(10):976–983. doi:10.1097/OPX.0b013e318157ac9e
   PubMed Web of Science ®Google Scholar
• Noguchi K, Gel YR, Brunner E, Konietschke F. nparLD: an R software package for the nonparametric analysis of longitudinal data in factorial experiments. J Statistical Software. 2012;50(12):1–23. doi:10.18637/jss.v050.i12
   PubMed Web of Science ®Google Scholar
• Hom MM, Nguyen AL, Bielory L. Allergic conjunctivitis and dry eye syndrome. Ann Allergy Asthma Immunol. 2012;108(3):163–166. doi:10.1016/j.anai.2012.01.006
   PubMed Web of Science ®Google Scholar
• Hellenthal KEM, Brabenec L, Gross ER, et al. TRP channels as sensors of aldehyde and oxidative stress. Biomolecules. 2021;11(10). doi:10.3390/biom11101401
   PubMed Web of Science ®Google Scholar
• Guivernau M, Baraona E, Lieber CS. Acute and chronic effects of ethanol and its metabolites on vascular production of prostacyclin in rats. J Pharmacol Exp Ther. 1987;240(1):59–64.
   PubMed Web of Science ®Google Scholar
• McMullin D, Clark D, Cavanagh B, et al. A post-acute ocular tolerability comparison of topical Reproxalap 0.25% and Lifitegrast 5% in patients with dry eye disease. Clin Ophthalmol. 2021;15:3889–3900. doi:10.2147/opth.S327691
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA Adverse Event Reporting System (FAERS). US Food and Drug Administration. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-adverse-event-reporting-system-faers. Accessed October 7, 2023.
   Google Scholar
• Pfaar O, Calderon MA, Andrews CP, et al. Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future - an EAACI Position Paper. Allergy. 2017;72(7):1035–1042. doi:10.1111/all.13133
   PubMed Web of Science ®Google Scholar